Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
Nature Reviews Drug Discovery: Protein Degraders Push into Novel Target Space
Our CEO, Nello Mainolfi, was interviewed by Nature Reviews Drug Discovery to discuss how targeted protein degradation can unlock previously intractable disease targets, including our STAT6 and IRAK4 degraders in immunology.
PharmaVoice 100 Top Industry Leaders: Dr. Jared Gollob, Chief Medical Officer
A physician by training, Dr. Jared Gollob’s biopharma career has been rooted in the belief that patients’ needs come first. And it’s one he carries with him as chief medical officer of Kymera Therapeutics, a clinical-stage biotech targeting diseases once considered undruggable.
Dermatology Times: Study Highlights KT-474’s Effectiveness in Targeting IRAK4 for Hidradenitis Suppurativa and Other Inflammatory Diseases
Dermatology Times spoke with Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, to discuss the role of IRAK4 expression and degradation in HS, as well as the potential of KT-474 in immuno-inflammatory diseases.
BiotechTV: Nello Mainolfi Shares an Update on Kymera and the Progress of the Protein Degradation Field
Nello gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has discovered since the last time BiotechTV visited the company one year ago.
Drug Target Review: Women in STEM with Juliet Williams
As part of their series highlighting women in STEM, Drug Target Review spoke to Juliet Williams, Head of Research at Kymera. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver results in previously undruggable conditions.
PharmaLeaders: Upending Traditional Wisdom at DDW, an Interview with Nello Mainolfi, PhD
PharmaLeaders had the chance to discuss Kymera’s exciting progress with Founder, President and CEO, Nello Mainolfi, Ph.D.
Boston Business Journal: Biotech Upgrades to New Watertown Digs with Triple the Space
The Boston Business Journal highlighted Kymera’s recent move to enable the expansion of our innovative R&D capabilities and support our growing team’s vibrant on-site presence as we work toward delivering life-changing medicines to patients.
Scrip: Kymera Puts Emphasis On Immunology In New Growth Phase
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.
Endpoints News: Kymera doubles down on protein degraders for immunology, chasing Dupixent and Sotyktu
Looking to further expand the reach of protein degraders beyond cancer, Kymera Therapeutics revealed two new programs Thursday morning that it hopes will compete with some of the hottest immunology drugs on the market.
Genetic Engineering & Biotechnology News: Up-to-$2B Sanofi Collaboration Pays Off for Kymera
Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) therapies for patients with immune-inflammatory diseases.